Sabinsa opens new manufacturing facility in India for nutraceutical and active pharmaceutical ingredients

The inaugural opening of Sami-Sabinsa’s new Sami Nutraceuticals facility in Hassan, India. Photo from Sabinsa.

Sabinsa Corp.’s parent company, Sami-Sabinsa Group, has opened a new facility in India for manufacturing nutraceutical and active pharmaceutical ingredients. The new facility is located at Hassan in the State of Karnataka, India. The 10-acre site is Sami-Sabinsa’s eighth manufacturing facility.

Unit-1 of the facility, called Sami Nutraceuticals Pvt. Ltd., will produce ingredients like calebin-A, resveratrol, SabiWhite pterostilbene, urolithins, and more. The Sami Nutraceuticals facility includes sophisticated quality-control and process-development labs. “An important feature of this new facility is its Zero Liquid Discharge (ZLD) capability, which minimizes the production-associated ecological footprint,” the company said in a press release. The $18 million facility can produce 88 tons of active nutraceutical ingredients (ANI) and active pharmaceutical ingredients (API) per annum. The facility features 18 reactors (including eight glass-line reactors), two hydrogenators, and specialized equipment like agitated nutsche filter dryers (ANFD), centrifuges, and Rotocone vacuum dryers.

Unit-2 of the facility, built on 15 acres of land, is nearing completion. It will house three production blocks: one for curcumin production and two for multipurpose herbal extracts.